- Home
- ZJYL vs ANEB Comparison
ZJYL vs ANEB Comparison
Compare ZJYL & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZJYL
- ANEB
- Stock Information
- Founded
- ZJYL 2006
- ANEB 2020
- Country
- ZJYL China
- ANEB United States
- Employees
- ZJYL N/A
- ANEB N/A
- Industry
- ZJYL Industrial Specialties
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- ZJYL Consumer Discretionary
- ANEB Health Care
- Exchange
- ZJYL Nasdaq
- ANEB Nasdaq
- Market Cap
- ZJYL 111.3M
- ANEB 111.8M
- IPO Year
- ZJYL 2023
- ANEB 2021
- Fundamental
- Price
- ZJYL $0.27
- ANEB $2.50
- Analyst Decision
- ZJYL
- ANEB Buy
- Analyst Count
- ZJYL 0
- ANEB 2
- Target Price
- ZJYL N/A
- ANEB $8.00
- AVG Volume (30 Days)
- ZJYL 2.8M
- ANEB 21.4K
- Earning Date
- ZJYL 08-20-2025
- ANEB 11-14-2025
- Dividend Yield
- ZJYL N/A
- ANEB N/A
- EPS Growth
- ZJYL N/A
- ANEB N/A
- EPS
- ZJYL 0.01
- ANEB N/A
- Revenue
- ZJYL $22,826,624.00
- ANEB N/A
- Revenue This Year
- ZJYL N/A
- ANEB N/A
- Revenue Next Year
- ZJYL N/A
- ANEB N/A
- P/E Ratio
- ZJYL $21.83
- ANEB N/A
- Revenue Growth
- ZJYL 13.42
- ANEB N/A
- 52 Week Low
- ZJYL $0.22
- ANEB $0.80
- 52 Week High
- ZJYL $2.20
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- ZJYL 32.63
- ANEB 45.45
- Support Level
- ZJYL $0.22
- ANEB $2.44
- Resistance Level
- ZJYL $0.28
- ANEB $2.65
- Average True Range (ATR)
- ZJYL 0.05
- ANEB 0.09
- MACD
- ZJYL 0.00
- ANEB -0.03
- Stochastic Oscillator
- ZJYL 26.09
- ANEB 14.63
About ZJYL JIN MEDICAL INTERNATIONAL LTD.
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.